XTX Topco Ltd Invests $1.39 Million in Repligen Co. (NASDAQ:RGEN)

XTX Topco Ltd acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 9,640 shares of the biotechnology company's stock, valued at approximately $1,388,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RGEN. Groupama Asset Managment grew its position in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares during the period. Raymond James Financial Inc. purchased a new position in Repligen during the fourth quarter valued at approximately $52,492,000. Allspring Global Investments Holdings LLC lifted its holdings in Repligen by 79.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. Alliancebernstein L.P. boosted its position in Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Repligen during the 4th quarter worth approximately $24,034,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $2.10 during midday trading on Friday, hitting $130.00. The company had a trading volume of 753,355 shares, compared to its average volume of 708,300. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The stock has a market cap of $7.30 billion, a price-to-earnings ratio of -254.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business's 50-day simple moving average is $140.37 and its 200-day simple moving average is $145.78.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

RGEN has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. StockNews.com cut Repligen from a "hold" rating to a "sell" rating in a report on Thursday. Canaccord Genuity Group dropped their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday. Finally, Evercore ISI assumed coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $176.82.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.